-
1
-
-
43549105864
-
Tumor necrosis factor alpha drugs in rheumatoid arthritis: Systematic review and metaanalysis of efficacy and safety
-
Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord. 2008;9:52.
-
(2008)
BMC Musculoskelet Disord
, vol.9
, pp. 52
-
-
Alonso-Ruiz, A.1
Pijoan, J.I.2
Ansuategui, E.3
Urkaregi, A.4
Calabozo, M.5
Quintana, A.6
-
2
-
-
38749141455
-
Systematic review: Comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis
-
Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med. 2008;148:124-34. (Pubitemid 351651555)
-
(2008)
Annals of Internal Medicine
, vol.148
, Issue.2
, pp. 124-134
-
-
Donahue, K.E.1
Gartlehner, G.2
Jonas, D.E.3
Lux, L.J.4
Thieda, P.5
Jonas, B.L.6
Hansen, R.A.7
Morgan, L.C.8
Lohr, K.N.9
-
3
-
-
37349006854
-
The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: A systematic literature review
-
DOI 10.1080/03009740701607067, PII 788637053
-
Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsoe B, Saxne T. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. Scand J Rheumatol. 2007;36:411-17. (Pubitemid 350293516)
-
(2007)
Scandinavian Journal of Rheumatology
, vol.36
, Issue.6
, pp. 411-417
-
-
Kristensen, L.E.1
Christensen, R.2
Bliddal, H.3
Geborek, P.4
Danneskiold-Samsoe, B.5
Saxne, T.6
-
4
-
-
72949116165
-
A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: A cochrane overview
-
Singh JA, Christensen R, Wells GA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ. 2009;181:787-96.
-
(2009)
CMAJ
, vol.181
, pp. 787-796
-
-
Singh, J.A.1
Christensen, R.2
Wells, G.A.3
-
5
-
-
70350343375
-
Efficacy of systemic treatments for moderate to severe plaque psoriasis: Systematic review and meta-analysis
-
Bansback N, Sizto S, Sun H, Feldman S, Willian MK, Anis A. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology. 2009;219:209-18.
-
(2009)
Dermatology
, vol.219
, pp. 209-218
-
-
Bansback, N.1
Sizto, S.2
Sun, H.3
Feldman, S.4
Willian, M.K.5
Anis, A.6
-
6
-
-
49749120663
-
Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: Meta-analysis of randomized controlled trials
-
Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol. 2008;159:513-26.
-
(2008)
Br J Dermatol
, vol.159
, pp. 513-526
-
-
Schmitt, J.1
Zhang, Z.2
Wozel, G.3
Meurer, M.4
Kirch, W.5
-
7
-
-
44349107161
-
Risks and benefits of tumor necrosis factor-α inhibitors in the management of psoriatic arthritis: Systematic review and metaanalysis of randomized controlled trials
-
Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol. 2008;35:883-90. (Pubitemid 351747132)
-
(2008)
Journal of Rheumatology
, vol.35
, Issue.5
, pp. 883-890
-
-
Saad, A.A.1
Symmons, D.P.M.2
Noyce, P.R.3
Ashcroft, D.M.4
-
8
-
-
36049048398
-
Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: A systematic review and economic evaluation
-
iii-iv
-
McLeod C, Bagust A, Boland A, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess. 2007;11:1-158, iii-iv.
-
(2007)
Health Technol Assess
, vol.11
, pp. 1-158
-
-
McLeod, C.1
Bagust, A.2
Boland, A.3
-
9
-
-
68149098843
-
Switching between tnfalpha antagonists in rheumatoid arthritis: Personal experience and review of the literature
-
Scrivo R, Conti F, Spinelli FR, et al. Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature. Reumatismo. 2009;61:107-17.
-
(2009)
Reumatismo
, vol.61
, pp. 107-117
-
-
Scrivo, R.1
Conti, F.2
Spinelli, F.R.3
-
10
-
-
33846239331
-
Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a Large UK National Cohort Study
-
DOI 10.1002/art.22331
-
Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2007;56:13-20. (Pubitemid 46106174)
-
(2007)
Arthritis and Rheumatism
, vol.56
, Issue.1
, pp. 13-20
-
-
Hyrich, K.L.1
Lunt, M.2
Watson, K.D.3
Symmons, D.P.M.4
Silman, A.J.5
-
11
-
-
80052856528
-
Patterns of biologic agent utilization among patients with rheumatoid arthritis: A retrospective cohort study
-
Ogale S, Hitraya E, Henk HJ. Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord. 2011;12:204.
-
(2011)
BMC Musculoskelet Disord
, vol.12
, pp. 204
-
-
Ogale, S.1
Hitraya, E.2
Henk, H.J.3
-
12
-
-
36749002002
-
Impact of concomitant dmard therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern sweden
-
Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther. 2006;8:R174.
-
(2006)
Arthritis Res Ther
, vol.8
-
-
Kristensen, L.E.1
Saxne, T.2
Nilsson, J.A.3
Geborek, P.4
-
13
-
-
50249107555
-
The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data
-
Kievit W, Adang EM, Fransen J, et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis. 2008;67:1229-34.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 1229-1234
-
-
Kievit, W.1
Adang, E.M.2
Fransen, J.3
-
14
-
-
66249124273
-
Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis
-
Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum. 2009;61:560-8.
-
(2009)
Arthritis Rheum
, vol.61
, pp. 560-568
-
-
Du Pan, S.M.1
Dehler, S.2
Ciurea, A.3
Ziswiler, H.R.4
Gabay, C.5
Finckh, A.6
-
15
-
-
70049109275
-
Tnf-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice
-
Marchesoni A, Zaccara E, Gorla R, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci. 2009;1173:837-46.
-
(2009)
Ann N Y Acad Sci
, vol.1173
, pp. 837-846
-
-
Marchesoni, A.1
Zaccara, E.2
Gorla, R.3
-
16
-
-
62449314082
-
Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide
-
Strangfeld A, Hierse F, Kekow J, et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis. 2009;68:1856-62.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 1856-1862
-
-
Strangfeld, A.1
Hierse, F.2
Kekow, J.3
-
17
-
-
74849094402
-
Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide danish danbio registry
-
Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62:22-32.
-
(2010)
Arthritis Rheum
, vol.62
, pp. 22-32
-
-
Hetland, M.L.1
Christensen, I.J.2
Tarp, U.3
-
18
-
-
84857233379
-
Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: Data from the spanish registry biobadaser 2.0
-
Gomez-Reino JJ, Rodriguez-Lozano C, Campos-Fernandez C, Montoro M, Descalzo MA, Carmona L. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. Ann Rheum Dis. 2012;71:382-5.
-
(2012)
Ann Rheum Dis
, vol.71
, pp. 382-385
-
-
Gomez-Reino, J.J.1
Rodriguez-Lozano, C.2
Campos-Fernandez, C.3
Montoro, M.4
Descalzo, M.A.5
Carmona, L.6
-
19
-
-
39449132386
-
The comparative one-year performance of anti-turmor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study
-
DOI 10.1002/art.23333
-
Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of antitumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008;59:234-40. (Pubitemid 351272960)
-
(2008)
Arthritis Care and Research
, vol.59
, Issue.2
, pp. 234-240
-
-
Heiberg, M.S.1
Koldingsnes, W.2
Mikkelsen, K.3
Rodevand, E.4
Kaufmann, C.5
Mowinckel, P.6
Kvien, T.K.7
-
20
-
-
34147219117
-
Survival of tnf antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the spanish registry biobadaser
-
Carmona L, Gomez-Reino JJ. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther. 2006;8:R72.
-
(2006)
Arthritis Res Ther
, vol.8
-
-
Carmona, L.1
Gomez-Reino, J.J.2
-
21
-
-
45349090538
-
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
-
DOI 10.1002/art.23721
-
Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic diseasemodifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-84. (Pubitemid 351847559)
-
(2008)
Arthritis Care and Research
, vol.59
, Issue.6
, pp. 762-784
-
-
Saag, K.G.1
Gim, G.T.2
Patkar, N.M.3
Anuntiyo, J.4
Finney, C.5
Curtis, J.R.6
Paulus, H.E.7
Mudano, A.8
Pisu, M.9
Elkins-Melton, M.10
Outman, R.11
Allison, J.J.12
Almazor, M.S.13
Bridges Jr., S.L.14
Chatham, W.W.15
Hochberg, M.16
Maclean, C.17
Mikuls, T.18
Moreland, L.W.19
O'Dell, J.20
Turkiewicz, A.M.21
Furst, D.E.22
more..
-
22
-
-
41949094481
-
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
-
DOI 10.1016/j.jaad.2008.02.039, PII S0190962208002739
-
Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826-50. (Pubitemid 351509656)
-
(2008)
Journal of the American Academy of Dermatology
, vol.58
, Issue.5
, pp. 826-850
-
-
Menter, A.1
Gottlieb, A.2
Feldman, S.R.3
Van Voorhees, A.S.4
Leonardi, C.L.5
Gordon, K.B.6
Lebwohl, M.7
Koo, J.Y.M.8
Elmets, C.A.9
Korman, N.J.10
Beutner, K.R.11
Bhushan, R.12
-
23
-
-
41949096736
-
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics
-
DOI 10.1016/j.jaad.2008.02.040, PII S0190962208002740
-
Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851-64. (Pubitemid 351509657)
-
(2008)
Journal of the American Academy of Dermatology
, vol.58
, Issue.5
, pp. 851-864
-
-
Gottlieb, A.1
Korman, N.J.2
Gordon, K.B.3
Feldman, S.R.4
Lebwohl, M.5
Koo, J.Y.M.6
Van Voorhees, A.S.7
Elmets, C.A.8
Leonardi, C.L.9
Beutner, K.R.10
Bhushan, R.11
Menter, A.12
-
24
-
-
0038423033
-
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis
-
DOI 10.1136/ard.62.9.817
-
Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2003;62:817-24. (Pubitemid 37026490)
-
(2003)
Annals of the Rheumatic Diseases
, vol.62
, Issue.9
, pp. 817-824
-
-
Braun, J.1
Pham, T.2
Sieper, J.3
Davis, J.4
Van Der Linden, Sj.5
Dougados, M.6
Van Der Heijde, D.7
|